On Thursday, Cantor Fitzgerald initiated coverage on Teladoc Health Inc. (NYSE:TDOC), a virtual healthcare services company, with an Overweight rating and a 12-month price target of $22.00. The firm's analysis suggests that the current market valuation underestimates Teladoc's potential, particularly noting its strong positioning for high free cash flow yield (FCFY), margin expansion, and multiple opportunities for further revenue growth.
The coverage initiation is based on a valuation that applies a 10x enterprise value to earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) multiple on Teladoc's estimated 2025 EBITDA of approximately $419 million. This also equates to a 1.5x EV/Revenue multiple on projected 2025 revenues of about $2.8 billion. Cantor Fitzgerald's stance reflects an expectation of Teladoc's transition to a focus on EBITDA growth, accompanied by a high FCFY.
According to the firm, Teladoc's current valuation does not reflect the premium typically accorded to service companies that exhibit standout cash flow and earnings quality within their peer group. The analyst highlighted that Teladoc is moving from prioritizing top-line growth to emphasizing margin expansion. However, the present valuation of 7.3x for 2025 EV/EBITDA does not seem to account for this strategic shift.
Furthermore, compared to its virtual healthcare peers, Teladoc's stock is trading at a significant discount—49% lower than the peer group's 2025 EV/EBITDA multiples and 13% lower on the EV/Revenue multiple. This is despite Teladoc's competitive advantages, which include a high EBITDA margin profile, superior FCFY, and robust free cash generation.
The firm's positive outlook on Teladoc is clear, as it anticipates the company to outperform within its sector based on these financial metrics.
InvestingPro Insights
Recent metrics provided by InvestingPro reveal a nuanced picture of Teladoc Health Inc. (NYSE:TDOC) that aligns with some of Cantor Fitzgerald's positive outlook. According to InvestingPro Data, Teladoc's market capitalization stands at $2.52 billion, with a revenue growth in the last twelve months as of Q4 2023 at 8.13%. This indicates a steady increase in the company's top-line figures, underscoring potential for further growth.
Moreover, the company's gross profit margin for the same period is notably high at 70.8%, suggesting efficient cost management relative to revenue. Despite these strengths, Teladoc is not expected to be profitable this year, with analysts revising their earnings downwards for the upcoming period. This aligns with the company's current price-to-earnings (P/E) ratio, which is negative at -10.82, reflecting the market's anticipation of future earnings rather than current profitability.
InvestingPro Tips highlight that Teladoc is trading near its 52-week low, which could present a buying opportunity for investors believing in the company's long-term strategy. Additionally, the firm's valuation implies a strong free cash flow yield, which may appeal to investors looking for companies with the potential to generate cash. For those interested in further insights, InvestingPro offers additional tips on Teladoc, which can be accessed at https://www.investing.com/pro/TDOC. Investors can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking a total of 9 InvestingPro Tips to aid in their investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.